stoxline Quote Chart Rank Option Currency Glossary
  
Clarus Therapeutics Holdings, Inc. (CRXT)
0.0475  -0.022 (-31.16%)    09-06 15:59
Open: 0.065
High: 0.0749
Volume: 2,737,134
  
Pre. Close: 0.069
Low: 0.0475
Market Cap: 0(M)
Technical analysis
2022-11-18 4:19:40 PM
Short term     
Mid term     
Targets 6-month :  0.08 1-year :  0.1
Resists First :  0.07 Second :  0.08
Pivot price 0.04
Supports First :  0.04 Second :  0.01
MAs MA(5) :  0.04 MA(20) :  0.04
MA(100) :  0.15 MA(250) :  0.95
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  50.4 D(3) :  50.4
RSI RSI(14): 53.6
52-week High :  7.13 Low :  0.01
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CRXT ] has closed below upper band by 43.3%. Bollinger Bands are 73% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 44 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.07 - 0.08 0.08 - 0.08
Low: 0.05 - 0.05 0.05 - 0.05
Close: 0.05 - 0.05 0.05 - 0.05
Company Description

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.

Headline News

Wed, 01 Mar 2023
CLARUS THERAPEUTICS HOLDINGS, INC. : Bankruptcy or Receivership, Completion of Acquisition or Disposition of ... - Marketscreener.com

Mon, 05 Sep 2022
Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process ... - GlobeNewswire

Mon, 29 Aug 2022
Clarus Therapeutics (CRXT) Stock Plunges Ahead of Aug. 31 Delisting - InvestorPlace

Tue, 10 May 2022
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + ... - GlobeNewswire

Thu, 28 Apr 2022
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate) - Yahoo Finance

Mon, 25 Apr 2022
Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Shares Out 24 (M)
Shares Float 32 (M)
Held by Insiders 2.5 (%)
Held by Institutions 23.2 (%)
Shares Short 2,000 (K)
Shares Short P.Month 3,310 (K)
Stock Financials
EPS -26.02
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -1.17
Profit Margin -256.2 %
Operating Margin -271.8 %
Return on Assets (ttm) -89.6 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 72 %
Gross Profit (p.s.) 0.46
Sales Per Share 0.65
EBITDA (p.s.) -1.77
Qtrly Earnings Growth 0 %
Operating Cash Flow -54 (M)
Levered Free Cash Flow -43 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value -0.05
Price to Sales 0.07
Price to Cash Flow -0.03
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android